Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 91

Streptococcus Pneumoniae (Pneumococcus) Infections – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2012', provides an overview of the Streptococcus Pneumoniae (Pneumococcus) Infections therapeutic pipeline. This report provides information on the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections. 'Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Streptococcus Pneumoniae (Pneumococcus) Infections.
- A review of the Streptococcus Pneumoniae (Pneumococcus) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Streptococcus Pneumoniae (Pneumococcus) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae (Pneumococcus) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae (Pneumococcus) Infections pipeline depth and focus of Streptococcus Pneumoniae (Pneumococcus) Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutic Products under Development, Key Players in Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics, Streptococcus Pneumoniae (Pneumococcus) Infections Pipeline Overview, Streptococcus Pneumoniae (Pneumococcus) Infections Pipeline, Streptococcus Pneumoniae (Pneumococcus) Infections Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Streptococcus Pneumoniae (Pneumococcus) Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Streptococcus Pneumoniae (Pneumococcus) Infections
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics under Development by Companies
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Products under Development by Companies
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
ACE BioSciences A/S
Ceragenix Pharmaceuticals, Inc.
Forest Laboratories, Inc.
Intercell AG
Basilea Pharmaceutica Ltd.
SIGA Technologies, Inc.
Panacea Biotec Limited
Eurocine Vaccines AB
Mucosis B.V.
GlycoVaxyn AG
aRigen Pharmaceuticals, Inc.
Sinovac Biotech Ltd.
Genocea Biosciences, Inc.
NasVax Ltd.
Streptococcus Pneumoniae (Pneumococcus) Infections – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Pneumococcal Conjugate Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sortase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcus Antibodies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACE720 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcal Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PneuGEM Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPG 7909 + Pneumococcal Vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synflorix + Hiberix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heptavalent Pneumococcal Conjugate Vaccine + Polyvalent Pneumococcal Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2189242A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptococcus pneumoniae Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasal Pneumococcal Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ceftobiprole Medocaril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ceftaroline + Avibactam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prevenar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prevenar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S. Pneumoniae Paediatric Next Generation Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSA-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcal Vaccine Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcal Invasive Disease Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2189242A + GSK1024850A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V419 + Prevnar 13 + RotaTeq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcal Polysaccharides Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PlyD1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Drug Profile Updates
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Discontinued Products
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics - Dormant Products
Streptococcus Pneumoniae (Pneumococcus) Infections – Product Development Milestones
Featured News & Press Releases
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program
Apr 26, 2011: National Advisory Committee On Immunization Recommends On Use Of Prevnar 13
Mar 03, 2011: Sinovac Biotech Submits Clinical Trial Application To SFDA For Pneumococcal Conjugate Vaccine
Oct 29, 2010: Forest Receives FDA Approval For Teflaro For Treatment Of Community-Acquired Bacterial Pneumonia And Acute Bacterial Skin And Skin Structure Infection
Oct 15, 2010: Cempra To Present New Data On Solithromycin At Annual Meeting Of Infectious Diseases Society Of America
Sep 09, 2010: Cempra Presents New Data On Solithromycin At 50th Interscience Conference On Antimicrobial Agents And Chemotherapy
Sep 08, 2010: Cempra Initiates Phase I Study Of Intravenous Formulation Of Solithromycin
Sep 08, 2010: Cempra Initiates Phase II Study With Oral Formulation Of Solithromycin
Jul 12, 2009: NasVax: Closing Share Purchase Agreement Of Protea Vaccine Technologies
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H1 2012
Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
GlaxoSmithKline plc, H1 2012
Merck & Co., Inc., H1 2012
ACE BioSciences A/S, H1 2012
Ceragenix Pharmaceuticals, Inc., H1 2012
Forest Laboratories, Inc., H1 2012
Intercell AG, H1 2012
Basilea Pharmaceutica Ltd., H1 2012
SIGA Technologies, Inc., H1 2012
Panacea Biotec Limited, H1 2012
Eurocine Vaccines AB, H1 2012
Mucosis B.V., H1 2012
GlycoVaxyn AG, H1 2012
aRigen Pharmaceuticals, Inc., H1 2012
Sinovac Biotech Ltd., H1 2012
Genocea Biosciences, Inc., H1 2012
NasVax Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Drug Profile Updates
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Discontinued Products
Streptococcus Pneumoniae (Pneumococcus) Infections Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections, H1 2012
Products under Development for Streptococcus Pneumoniae (Pneumococcus) Infections – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Competitor Analysis: Pneumococcal and Streptococcal Vaccines
• Streptococcal Infections - Pipeline Review, H2 2012
• Competitor Analysis: Streptococcal Vaccines and Antibodies
• Rotavirus Infections – Pipeline Review, H1 2013
• Herpes Simplex Infections - Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013
• Community-Acquired Infections – Pipeline Review, H1 2013
• Meningitis - Pipeline Review, H2 2012
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013